Ardelyx Investors Offered Role in Securities Fraud Lawsuit
Schall, Brown & Schwartz LLP is notifying investors in Ardelyx Inc. of a class action lawsuit alleging securities fraud due to allegedly misleading statements made by the company.
Shareholders of Ardelyx Inc. (NASDAQ: ARDX) have the opportunity to participate in a class action lawsuit alleging violations of federal securities laws, according to the law firm Schall, Brown & Schwartz LLP (SBS). The lawsuit claims that the company made false and misleading statements to the market regarding its business operations.
The core of the complaint centers on alleged misrepresentations about reimbursement barriers affecting patient access to Ardelyx's drugs, XPHOZAH and IBSRELA. The suit contends that delays in new patient starts and prescription fulfillment, attributed to stringent prior authorization and step-edit requirements, negatively impacted the company's commercial performance, and that this truth was not adequately disclosed to investors.
The alleged class period for these claims spans from January 13, 2025, to August 6, 2026. SBS is encouraging investors who purchased Ardelyx stock during this timeframe and suffered losses to contact the firm to discuss their potential roles, including the possibility of serving as lead plaintiff.
While appointment as lead plaintiff is not a prerequisite for participation in any potential recovery, it allows certain shareholders to guide the litigation. The deadline to seek appointment as lead plaintiff is November 16, 2026. The firm notes that class certification has not yet occurred, and investors can remain absent class members if they take no action. Further details are available on the Schall, Brown & Schwartz LLP website.